1.WHO Guidelines Approved by the Guidelines Review Committee. WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. edn. Geneva: World Health Organization.2018.
2.Wang JL, Chang CH, Lin JW, et al. Infection, antibiotic therapy and risk of colorectal cancer: a nationwide nested case-control study in patients with Type 2 diabetes mellitus. International journal of cancer. 2014; 135:956–967.
3.Mohr KI.History of Antibiotics Research. Current topics in microbiology and immunology. 2016; 398:237–272.
4.Velicer CM, Heckbert SR, Lampe JW, et al. Antibiotic use in relation to the risk of breast cancer. Jama. 2004;291:827–835.
5.Zhang H, Garcia Rodriguez LA, Hernandez-Diaz S. Antibiotic use and the risk of lung cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008; 17:1308–1315.
6.Tamim HM, Hanley JA, Hajeer AH, et al. Risk of breast cancer in relation to antibiotic use. Pharmacoepidemiology and drug safety. 2008; 17:144–150.
7.Tamim HM, Hajeer AH, Boivin JF, et al. Association between antibiotic use and risk of prostate cancer. International journal of cancer. 2010;127:952–960.
8.Dik VK, van Oijen MG, Smeets HM, et al. Frequent Use of Antibiotics Is Associated with Colorectal Cancer Risk: Results of a Nested Case-Control Study. Digestive diseases and sciences. 2016; 61:255–264.
9.Yang B, Hagberg KW, Chen J, et al. Associations of antibiotic use with risk of primary liver cancer in the Clinical Practice Research Datalink. British journal of cancer. 2016; 115:85–89.
10.Tamim HM, Musallam KM, Al Kadri HM,et al. Antibiotic use and risk of gynecological cancer. European journal of obstetrics, gynecology, and reproductive biology. 2011; 159:388–393.
11.Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
12.Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2013. Available from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
13.Russell B, Garmo H, Beckmann K,et al. A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0. PloS one. 2018; 13:e0195690.
14.Ostgard LSG, Norgaard M, Pedersen L, et al. Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study. British journal of haematology. 2018; 181:205–214.
15.Boursi B, Mamtani R, Haynes K, et al. Recurrent antibiotic exposure may promote cancer formation—Another step in understanding the role of the human microbiota? European journal of cancer. 2015; 51:2655–2664.
16.Boursi B, Haynes K, Mamtani R,et al. Impact of antibiotic exposure on the risk of colorectal cancer. Pharmacoepidemiology and drug safety. 2015; 24:534–542.
17.Wirtz HS, Buist DS, Gralow JR, et al. Frequent antibiotic use and second breast cancer events. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013; 22:1588–1599.
18.Rasmussen ML, Hjalgrim H, Molgaard-Nielsen D, et al. Antibiotic use and risk of non-Hodgkin lymphomas. International journal of cancer. 2012; 131:E1158–1165.
19.Daniels NA, Chen YH, Bent S. Antibiotic and anti-inflammatory use and the risk of prostate cancer. BMC research notes. 2009; 2:57.
20.Kilkkinen A, Rissanen H, Klaukka T, et al.Antibiotic use predicts an increased risk of cancer. International journal of cancer. 2008; 123:2152–2155.
21.Friedman GD, Oestreicher N, Chan J,, et al. Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006; 15:2102–2106.
22.Fall K, Ye W, Nyren O. Antibiotic treatment and risk of gastric cancer. Gut. 2006; 55:793–796.
23.Sorensen HT, Skriver MV, Friis S, et al. Use of antibiotics and risk of breast cancer: a population-based case-control study. British journal of cancer 2005, 92(3):594–596.
24.Kaye JA, Jick H: Antibiotics and the risk of breast cancer. Epidemiology. 2005; 16:688–690.
25.Garcia Rodriguez LA, Gonzalez-Perez A. Use of antibiotics and risk of breast cancer. American journal of epidemiology. 2005;161:616–619.
26.Didham RC, Reith DM, McConnell DW, et al. Antibiotic exposure and breast cancer in New Zealand. Breast cancer research and treatment. 2005; 92:163–167.
27.Kato I, Koenig KL, Baptiste MS, et al. History of antibiotic use and risk of non-Hodgkin’s lymphoma (NHL). International journal of cancer. 2003; 107:99–105.
28.Kamada N, Seo SU, Chen GY, et al. Role of the gut microbiota in immunity and inflammatory disease. Nature reviews Immunology. 2013; 13:321–335.
29.Cheng M, Qian L, Shen G, Bian G, et al. Microbiota modulate tumoral immune surveillance in lung through a gammadeltaT17 immune cell-dependent mechanism. Cancer research 2014; 74:4030–4041.
30.Schwabe RF, Jobin C. The microbiome and cancer. Nature reviews Cancer. 2013, 13:800–812.
31.Dethlefsen L, Huse S, Sogin ML, Relman DA: The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS biology. 2008; 6:e280.
32.Perez-Cobas AE, Gosalbes MJ, Friedrichs A, et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut. 2013; 62:1591–1601.
33.Jakobsson HE, Jernberg C, Andersson AF, et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PloS one. 2010; 5:e9836.
34.Josefsdottir KS, Baldridge MT. Antibiotics impair murine hematopoiesis by depleting the intestinal microbiota. Blood. 2017; 129:729–739.
35.Purchiaroni F, Tortora A, Gabrielli M, et al. The role of intestinal microbiota and the immune system. European review for medical and pharmacological sciences 2013, 17:323–333.
36.Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD–1-based immunotherapy against epithelial tumors. science.2018; 359:91–97.